Neurocognitive Assessment and Pharmacotherapy Towards Prevention of Schizophrenia: What Can We Learn from First Episode Psychosis?

참고문헌 (74)

1. Kurachi M, "Generation of physiopathology of schizophrenia--a hypothesis of temporal-frontal lobe 2- step development", Seishin Shinkeigaku Zasshi, 106, pp.1180~1185 (2004)
2. Malla A, "First episode psychosis: Integrating neurobiological and psychosocial determinants of outcome", Biol Psychiatry, 61, pp.2S~3S. (2007)
3. Sumiyoshi T, "Neurocognitive assessment and pharmacotherapy: Towards prevention of psychosis. In Workshop “First episode psychosis: Integrating neurobiological and psychosocial determinants of outcome", 62nd Annual Meeting of Society of Biologi-cal Psychiatry (2007)
4. Sumiyoshi T, "Neurocognitive assessment and pharmacotherapy: Towards prevention of psychosis. In Symposium “First episode psychosis: Integrating neurobiological and psychosocial determinants of outcome", 2nd International Congress of Biological Psychiatry (2007)
5. Lepage M, "Neurocognition, neuroimaging and insight in first episode psychosis: Common determinants of outcome", 2nd International Congress of Biological Psychiatry (2007)
6. Keshavan M, "ntegrating biologic and psychosocial determinants of outcome", 62nd Annual Meeting of Society of Biological Psychiatry (2007)
7. Kenny JT, "Attention and higher cortical functions in schizophrenia", J Neuropsychiatry Clin Neurosci, 3, pp.269~275 (1991)
8. McGurk SR, "The role of cognition in vocational functioning in schizophrenia", Schizophr Res, 45, pp.175~184 (2000)
9. Meltzer HY, "Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment", Neuropsychopharmacology, 14, pp.27S~33S (1996)
10. Sumiyoshi C, "Atypical antipsychotic drugs and organization of long-term semantic memory: multidimensional scaling and cluster analyses of category fluency performance in schizophrenia", Int J Neuropsychopharmacol, 9, pp.677~683 (2006)
11. Mohamed S, "Generalized cognitive deficits in schizophrenia: a study of firstepisode patients", Arch Gen Psychiatry, 56, pp.749~754 (1999)
12. Keefe RS, "Defining a cognitive function decrement in schizophrenia", Biol Psychiatry, 57, pp.688~691 (2005)
13. Nieuwenstein MR, "Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies", J Psychiatr Res, 35, pp.119~125 (2001)
14. Sumiyoshi C, "Semantic structure in schizophrenia as assessed by the category fluency test: effect of verbal intelligence and age of onset", Psychiatry Res, 105, pp.187~199 (2001)
15. Sumiyoshi C, "Effect of orthography on the verbal fluency performance in schizophrenia: examination using Japanese patients", Schizophr Res, 69, pp.15~22 (2004)
16. Sumiyoshi C, "Disorganization of semantic memory underlies alogia in schizophrenia: an analysis of verbal fluency performance in Japanese subjects", Schizophr Res, 74, pp.91~100 (2005)
17. Sumiyoshi C, "Semantic memory deficits based on category fluency performance in schizophrenia: Similar impairment patterns of semantic organization across Turkish and Japanese patients", Psychiatry Res
18. Kaneda Y, "Brief assessment of cognition in schizophrenia: validation of the Japanese version", Psychiatry Clin Neurosci, 61, pp.602~609 (2007)
19. Matsui M, "Cognitive functioning related to quality of life in schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.280~287 (2008)
20. Matsui M, "Neuropsychological profile in patients with schizotypal personality disorder or schizophrenia", Psychol Rep, 94, pp.387~397 (2004)
21. Yung AR, "Testing the Ultra High Risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people", Schizophr Res, 84, pp.57~66 (2006)
22. Stirling J, "Neurocognitive function and outcome in first-episode schizophrenia: a 10-year follow-up of an epidemiological cohort", Schizophr Res, 65, pp.75~86 (2003)
23. Addington J, "Cognitive functioning in first episode psychosis: initial presentation", Schizophr Res, 62, pp.59~64 (2003)
24. Hawkins KA, "Neuropsychological status of subjects at high risk for a first episode of psychosis", Schizophr Res, 67, pp.115~122 (2004)
25. Lencz T, "Generalized and specific neurocognitive deficits in prodromal schizophrenia", Biol Psychiatry, 59, pp.863~871 (2006)
26. Whyte MC, "Neuropsychological performance over time in people at high risk of developing schizophrenia and controls", Biol Psychiatry, 59, pp.730~739 (2006)
27. Keefe RS, "A longitudinal study of neurocognitive function in individuals at-risk for psychosis", Schizophr Res, 88, pp.26~35 (2006)
28. Rund BR, "The course of neurocognitive functioning in firstepisode psychosis and its relation to premorbid adjustment, duration of untreated psychosis, and relapse", Schizophr Res, 91, pp.132~140 (2007)
29. Saeedi H, "The association of insight with psychotic symptoms, depression, and cognition in early psychosis: a 3-year follow-up", Schizophr Res, 89, pp.123~128 (2007)
30. Green MF, "What are the functional consequences of neurocognitive deficits in schizophrenia", Am J Psychiatry, 153, pp.321~330 (1996)
31. Kawasaki Y, "Reduced auditory P300 amplitude, medial temporal volume reduction and psychopathology in schizophrenia", Schizophr Res, 26, pp.107~115 (1997)
32. Kawasaki Y, "Voxel-based analysis of P300 electrophysiological topography associated with positive and negative symptoms of schizophrenia", Schizophr Res, 94, pp.164~171 (2007)
33. Nieman DH, "Clinical and neuropsychological correlates of the P300 in schizophrenia", Schizophr Res, 55, pp.105~113 (2002)
34. Umbricht D, "Effects of clozapine on auditory event-related potentials n schizophrenia", Biol Psychiatry, 44, pp.716~725 (1998)
35. Sumiyoshi T, "Electrical brain activity and response to olanzapine in schizophrenia: a study with LORETA images of P300", Prog Neuropsychopharmacol Biol Psychiatry, 30, pp.1299~1303 (2006)
36. Higuchi Y, "Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300", Schizophr Res, 101, pp.320~330 (2008)
37. Bramon E, "Is the P300 wave an endophenotype for schizophrenia? A meta-analysis and a family study", Neuroimage, 27, pp.960~968 (2005)
38. Pascual-Marqui RD, "Review of methods for solving the EEG inverse problem", Int J Bioelectromagnetism, 1, pp.75~86 (1999)
39. Takahashi T, "Morphologic alterations of the parcellated superior temporal gyrus in schizophrenia spectrum", Schizophr Res, 83, pp.131~143 (2006)
40. Meltzer HY, "Atypical antipsychotic drugs improve cognition in schizophrenia", Biol Psychiatry, 53, pp.265~267 (2003)
41. Meltzer HY, "Les nouveaux antipsychotiques; Perspective clinique. In: Medicaments antipsychotiques: evolution ou revolution", pp.63~90 (2001), ETICOM-Acanthe
42. Sumiyoshi T, "The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia", Schizophr Res, 59, pp.7~16 (2003)
43. Sumiyoshi T, "Relapse in schizophrenia. In: Psychiatry Highlights 2001-02. Vol 1", pp.27~35 (2002), Health Press
44. Chung YC, "Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism", Brain Res, 1023, pp.54~63 (2004)
45. Ichikawa J, "Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum", Neuropsychopharmacology, 26, pp.325~339 (2002)
46. Ichikawa J, "5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release", J Neurochem, 76, pp.1521~1531 (2001)
47. Kuroki H, "Effect of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontalcortex and nucleus accumbens", J Pharmacol Exp Ther, 288, pp.774~781 (1998)
48. Parada MA, "Selective action of acute systemic clozapine on acetylcholine release in the rat prefrontal cortex by reference to the nucleus accumbens and striatum", J Pharmacol Exp Ther, 281, pp.582~588 (1997)
49. Meltzer HY, "Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values", J Pharmacol Exp Ther, 251, pp.238~246 (1989)
50. Stockmeier CA, "Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors", J Pharmacol Exp Ther, 266, pp.1374~1384 (1993)
51. Sumiyoshi T, "Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy", Neuropsychopharmacology, 12, pp.57~64 (1995)
52. Araki T, "Perospirone in the treatment of schizophrenia: effect on verbal memory organization", Prog Neuropsychopharmacol Biol Psychiatry, 30, pp.204~208 (2006)
53. Mori K, "Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia", Prog Neuropsychopharmacol Biol Psychiatry, 28, pp.659~665 (2004)
54. Hori H, "Antipsychotic medication and cognitive function in schizophrenia", Schizophr Res, 86, pp.138~146 (2006)
55. Sumiyoshi T, "Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia", Psychopharmacology (Berl), 177, pp.79~83 (2004)
56. McGorry PD, "Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms", Arch Gen Psychiatry, 59, pp.921~928 (2002)
57. McGlashan TH, "Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis", Am J Psychiatry, 163, pp.790~799 (2006)
58. Reilly JL, "Adverse effects of risperidone on spatial working memory in first-episode schizophrenia", Arch Gen Psychiatry, 63, pp.1189~1197 (2004)
59. Reilly JL, "Antipsychotic drugs exacerbate impairment on a working memory task in first-episode schizophrenia", Biol Psychiatry, 62, pp.818~821 (2007)
60. Sumiyoshi T, "A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine", J Clin Psychopharmacol, 24, pp.345~348 (2004)
61. Sumiyoshi T, "The effect of hypertension and obesity on the development of diabetes mellitus in patients treated with atypical antipsychotic drugs", J Clin Psychopharmacol, 24, pp.452~454 (2004)
62. Matsuoka T, "Effect of MK-801 on gene expressions in the amygdala of rats", Synapse, 62, pp.1~7 (2008)
63. Seo T, "T-817MA, a novel neurotrophic compound, ameliorates phencyclidine-induced disruption of sensorimotor gating", Psychopharmacology (Berl), 197, pp.457~464 (2008)
64. Glantz LA, "Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia", Arch Gen Psychiatry, 57, pp.65~73 (2000)
65. Lieberman JA, "Antipsychotic drug effects on brain morphology in first-episode psychosis", Arch Gen Psychiatry, 62, pp.361~370 (2005)
66. Cosi C, "Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation", Brain Res, 1043, pp.32~41 (2005)
67. Uehara T, "Role of 5-HT1A receptors in the modulation of stress-induced lactate metabolism in the medial prefrontal cortex and basolateral amygdala", Psychopharmacology (Berl), 186, pp.218~225 (2006)
68. Sumiyoshi T, "Essential polyunsaturated fatty acids and social cognition in schizophrenia", Psychiatry Res, 157, pp.87~93 (2008)
69. Sumiyoshi T, "Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment", Am J Psychiatry, 158, pp.1722~1725 (2001)
70. Sumiyoshi T, "The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia", Biol Psychiatry, 49, pp.861~868 (2001)
71. Sumiyoshi T, "Effect of adjunctive treatment with serotonin- 1A agonist tandospirone on memory functions in schizophrenia", J Clin Psychopharmacol, 20, pp.386~388 (2000)
72. Sumiyoshi T, "Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study", Schizophr Res, 95, pp.158~168 (2007)
73. Sumiyoshi T, "Serotonin 1A receptors in memory function", Am J Psychiatry, 161, pp.1505~ (2004)
74. Kawasaki Y, "Clinical service for young people at risk for developing psychosis in Toyama", 3rd Annual Meeting of Japanese Society of Schizophrenia Research (2008)

관련 논문AI추천